Evrópusambandið - eistneska - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - eesnäärmevähk - terapeutilised radiofarmatseutilised ühendid - xofigo on näidustatud kastreeruva resistentsusega eesnäärmevähiga täiskasvanute, sümptomaatiliste luu metastaaside raviks ja teadaolevate vistseraalsete metastaaside puudumisel.

Eistland - eistneska - Ravimiamet

rotexmedica gmbh - kiniin - süstelahus - 600mg 2ml 2ml 100tk; 600mg 2ml 2ml 10tk

Eistland - eistneska - Ravimiamet

kalceks as - morfiin - süstelahus - 10mg 1ml 1ml 10tk

Eistland - eistneska - Ravimiamet

sterop overseas s.a. laboratories - efedriin - süstelahus - 50mg 1ml 1ml 100tk

Eistland - eistneska - Ravimiamet

grindeks as - morfiin - süstelahus - 10mg 1ml 1ml 10tk

Eistland - eistneska - Ravimiamet

tov kharkivske farmatsevtychne pidpryemstvo zdorovya narodu - johimbiinhape - tablett - 5mg 50tk

Eistland - eistneska - Ravimiamet

gland pharma limited - kiniin - süstelahus - 300mg 1ml 2ml 100tk

Eistland - eistneska - Ravimiamet

orion pharma - metüülprednisoloon+bupivakaiin - süstesuspensioon - 40mg+5mg 1ml 2ml 1tk

Evrópusambandið - eistneska - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Evrópusambandið - eistneska - EMA (European Medicines Agency)

itm medical isotopes gmbh - lutetium (177lu) chloride - radionukliidi pildistamine - terapeutilised radiofarmatseutilised ühendid - endolutsiinbeta on radiofarmatseutiline prekursor ja see ei ole ette nähtud patsientide otseseks kasutamiseks. seda tuleb kasutada ainult spetsiaalselt välja töötatud ja lutetiumi (177lu) kloriidi radioaktiivse märgistamise jaoks kinnitatud kandemolekulide radiomärgistamiseks.